CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.
作者信息
Marino Federica Zito, Accardo Marina, Franco Renato
机构信息
Pathology Unit, Università della Campania Luigi Vanvitelli, Napoli, Italy.
Pathology Unit, Istituto dei Tumori 'Fondazione G. Pascale', Napoli, Italy.
出版信息
J Thorac Dis. 2017 Jul;9(7):1759-1762. doi: 10.21037/jtd.2017.06.27.
Abstract
摘要
相似文献
1
CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.非小细胞肺癌中的CRISPR条形码技术：从肿瘤内基因异质性建模到癌症治疗应用
J Thorac Dis. 2017 Jul;9(7):1759-1762. doi: 10.21037/jtd.2017.06.27.
2
Modeling intratumor heterogeneity through CRISPR-barcodes.通过CRISPR条形码对肿瘤内异质性进行建模。
Mol Cell Oncol. 2016 Sep 6;3(6):e1227894. doi: 10.1080/23723556.2016.1227894. eCollection 2016.
3
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.用于肿瘤内基因异质性建模和致癌驱动基因突变功能分析的CRISPR条形码技术
Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.
4
Who Is in the Driver's Seat: Tracing Cancer Genes Using CRISPR-Barcoding.谁在掌控局面：使用 CRISPR 条形码追踪癌症基因。
Mol Cell. 2016 Aug 4;63(3):352-4. doi: 10.1016/j.molcel.2016.07.013.
5
The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.TP53突变对早期非小细胞肺癌患者预后的影响可能取决于突变的肿瘤内异质性。
Mol Carcinog. 2015 Feb;54(2):93-101. doi: 10.1002/mc.22077. Epub 2013 Sep 4.
6
Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.分析混合型肺腺癌中 EGFR 突变的肿瘤内异质性。
Clin Lung Cancer. 2013 Sep;14(5):521-6. doi: 10.1016/j.cllc.2013.04.005. Epub 2013 Jun 17.
7
Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.混合性肺腺癌中ALK重排的肿瘤内异质性及EGFR突变的同质性
PLoS One. 2015 Sep 30;10(9):e0139264. doi: 10.1371/journal.pone.0139264. eCollection 2015.
8
Intratumor Heterogeneity in Breast Cancer.乳腺癌中的肿瘤内异质性
Adv Exp Med Biol. 2016;882:169-89. doi: 10.1007/978-3-319-22909-6_7.
9
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.肿瘤内雌激素受体异质性与致命性乳腺癌的长期风险
J Natl Cancer Inst. 2018 Jul 1;110(7):726-733. doi: 10.1093/jnci/djx270.
10
Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.多区域测序揭示了TP53驱动的非小细胞肺癌中驱动基因突变的肿瘤内异质性。
Int J Cancer. 2017 Jan 1;140(1):103-108. doi: 10.1002/ijc.30437. Epub 2016 Oct 3.
引用本文的文献
1
Kernel Fusion Method for Detecting Cancer Subtypes via Selecting Relevant Expression Data.通过选择相关表达数据检测癌症亚型的核融合方法
Front Genet. 2020 Sep 10;11:979. doi: 10.3389/fgene.2020.00979. eCollection 2020.
2
Overview on Clinical Relevance of Intra-Tumor Heterogeneity.肿瘤内异质性的临床相关性概述
Front Med (Lausanne). 2018 Apr 6;5:85. doi: 10.3389/fmed.2018.00085. eCollection 2018.
本文引用的文献
1
CRISPR-Cas9: from Genome Editing to Cancer Research.CRISPR-Cas9：从基因组编辑到癌症研究
Int J Biol Sci. 2016 Nov 4;12(12):1427-1436. doi: 10.7150/ijbs.17421. eCollection 2016.
2
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.用于肿瘤内基因异质性建模和致癌驱动基因突变功能分析的CRISPR条形码技术
Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.
3
Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma.克唑替尼对ALK阳性肺腺癌晚期复发的疗效
Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):e86-e88. doi: 10.1097/PAI.0000000000000328.
4
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.治疗ALK阳性非小细胞肺癌患者：最新证据与管理策略
Ther Adv Med Oncol. 2015 Sep;7(5):274-90. doi: 10.1177/1758834015590593.
5
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application.克服非小细胞肺癌中靶向治疗的耐药性：当前方法与临床应用
Ther Adv Med Oncol. 2015 Sep;7(5):263-73. doi: 10.1177/1758834015595048.
6
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.通过下一代测序评估EGFR突变型晚期肺腺癌的分子异质性及对吉非替尼的反应
Oncotarget. 2015 May 20;6(14):12783-95. doi: 10.18632/oncotarget.3727.
7
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.利用高复杂度条形码研究癌症治疗反应中的克隆动力学。
Nat Med. 2015 May;21(5):440-8. doi: 10.1038/nm.3841. Epub 2015 Apr 13.
8
Translational implications of tumor heterogeneity.肿瘤异质性的转化意义。
Clin Cancer Res. 2015 Mar 15;21(6):1258-66. doi: 10.1158/1078-0432.CCR-14-1429.
9
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.肺癌中酪氨酸激酶抑制剂耐药性发展的新兴模式。
J Clin Oncol. 2013 Nov 1;31(31):3987-96. doi: 10.1200/JCO.2012.45.2029. Epub 2013 Oct 7.
10
Cas9 as a versatile tool for engineering biology.Cas9 作为一种通用的基因编辑工具。
Nat Methods. 2013 Oct;10(10):957-63. doi: 10.1038/nmeth.2649.
Zotero 插件